[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
UBS issues a Buy rating for $PTCT after a positive discussion about its PKU treatment. The analyst call focused on the treatment paradigm and potential for a strong launch.
PTCT is a ticker symbol, likely representing a company or cryptocurrency.
Engagements 24-Hour Chart Data
Current Value: XX
Daily Average: XXX
1-Year High: XXXXX on 2025-07-14
1-Year Low: XX on 2025-07-19
Social Network | X |
---|---|
Engagements | XX |
Mentions 24-Hour Chart Data
Current Value: X
Daily Average: X
1-Year High: X on 2025-07-14
1-Year Low: X on 2025-07-14
Social Network | X |
---|---|
Mentions | X |
Creators 24-Hour Chart Data
X unique social accounts have posts mentioning $ptcts in the last XX hours which is no change from in the previous XX hours
Daily Average: X
1-Year High: X on 2025-07-14
1-Year Low: X on 2025-07-14
Top assets mentioned In the posts about $ptcts in the last XX hours
Vertex Protocol (VRTX) SuperRare (RARE)
Top topics mentioned In the posts about $ptcts in the last XX hours
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"UBS reiterated $PTCT Buy-$71 after they hosted a medical geneticist and professor of pediatrics who is an expert on PKU and treats320 patients. $BMRN $SRPT $JNJ $BIIB $NVS $RHHBY $LRMR $RARE $VRTX $EWTX $CAPR #KOL UBS added "Our discussion focused on the treatment paradigm in PKU with current management options (low-Phe diet Kuvan/sapropterin Palnynziq) as well as $PTCT's sepiapterin (recently approved in Europe as Sephience US FDA PDUFA 7/29). Overall we think the call was highly supportive of a strong potential launch for $PTCT's sepiapterin. Key takeaways from the call: 1) Potential for a"
@Quantumup1 on X 2025-07-14 16:12:31 UTC 3521 followers, 2237 engagements